<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">1904</id>
  <title>T3D1900</title>
  <common-name>Tris(4-bromophenyl)aminium hexachloroantimonate</common-name>
  <description>Tris(4-bromophenyl)aminium hexachloroantimonate is an exogenous organic compound with the formula C18H12Br3Cl6NSb. It exists as a solid at room temperature. Tris(4-bromophenyl)aminium hexachloroantimonate belongs to the halobenzenes, a subclass of benzene and substituted derivatives within the organic compounds. With an average molecular weight of 816.48 g/mol, Tris(4-bromophenyl)aminium hexachloroantimonate is a heavy molecule.

The compound is found in or released from two recorded sources, specifically electrical and electronic equipment such as antennas and amplifiers. It interacts with 19 recorded protein targets, including Glutathione S-transferase A1 (GSTA1), Glutathione S-transferase A2 (GSTA2), Glutathione S-transferase A3 (GSTA3), and Glutathione S-transferase Mu 4 (GSTM4), along with 15 other proteins. Trivalent antimony inhibits glutathione-S-transferases from human erythrocytes, which reduces their detoxification ability.</description>
  <cas>24964-91-8</cas>
  <pubchem-id>258027</pubchem-id>
  <chemical-formula>C18H12Br3Cl6NSb</chemical-formula>
  <weight>478.851990</weight>
  <appearance>White powder.</appearance>
  <melting-point></melting-point>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility></solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Inhalation (L741) ; oral (L741) ; dermal (L741)</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>The inhalation data suggests that the myocardium is a target of antimony toxicity. It is possible that antimony affects circulating glucose by interfering with enzymes of the glycogenolysis and gluconeogenesis pathways. The mechanism of action of antimony remains unclear. However, some studies suggest that antimony combines with sulfhydryl groups including those in several enzymes important for tissue respiration. The antidotal action of BAL depends on its ability to prevent or break the union between antimony and vital enzymes. Moreover, the The cause of death is believed to be essentially the same as that in acute arsenic poisoning. (T18, L741, A238)</mechanism-of-toxicity>
  <metabolism>Antimony is widely distributed throughout the body. The hair and skin contain the highest levels of antimony. The adrenal glands, lung, large intestine, trachea, cerebellum, and kidneys also contain relatively high levels of antimony. Blood is the main vehicle for the transport of absorbed antimony to various tissue compartments of the body. Antimony is a metal and, therefore, does not undergo catabolism. Antimony can covalently interact with sulfhydryl groups and phosphate, as well as numerous reversible binding interactions with endogenous ligands (e.g., proteins). It is not known if these interactions are toxicologically significant. Antimony is excreted via the urine and feces. Some of the fecal antimony may represent unabsorbed antimony that is cleared from the lung via mucociliary action into the esophagus to the gastrointestinal tract. (L741)</metabolism>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity (not listed by IARC). (L135)</carcinogenicity>
  <use-source>Breathing air, drinking water, and eating foods that contain antimony. Exposure can also occur through dermal or skin contact (L741).</use-source>
  <min-risk-level nil="true"/>
  <health-effects>Dermal exposure to antimony can cause antimony spots (papules and pustules around sweat and sebaceous glands). Antimony poisoning can also lead to pneumoconiosis. Alterations in pulmonary function and other effects including chronic bronchitis, chronic emphysema, inactive tuberculosis, pleural adhesions, and irritation can result from inhalation of antimony. Increased blood pressure can also result from antimony poisoning. Myocardial depression, vasodilation and fluid loss may cause shock with hypotension, electrolyte disturbances and acute renal failure. Cerebral oedema, coma, convulsions, and death are possible. (L741)</health-effects>
  <symptoms>Abdominal pain, vomiting, diarrhea can result from inhalation of antimony. Dyspnea, headache, vomiting,cough, conjunctivitis, and bloody purulent discharge from nose can result from inhalation exposure. Skin or eye contact can cause pain and redness of the exposed surface. (T64, L741)</symptoms>
  <treatment>EYES: irrigate opened eyes for several minutes under running water.
      
INGESTION: do not induce vomiting. Rinse mouth with water (never give anything by mouth to an unconscious person). Seek immediate medical advice.
      
SKIN: should be treated immediately by rinsing the affected parts in cold running water for at least 15 minutes, followed by thorough washing with soap and water. If necessary, the person should shower and change contaminated clothing and shoes, and then must seek medical attention.
      
INHALATION: supply fresh air. If required provide artificial respiration.</treatment>
  <created-at type="dateTime">2009-06-23T21:03:14Z</created-at>
  <updated-at type="dateTime">2026-08-19T22:43:45Z</updated-at>
  <interacting-proteins>No interacting proteins found.</interacting-proteins>
  <wikipedia nil="true"/>
  <uniprot-id nil="true"/>
  <kegg-compound-id></kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id></chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id>Tris(4-bromophenyl)aminium hexachloroantimonate</stitch-id>
  <drugbank-id nil="true"/>
  <pdb-id nil="true"/>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>Cl[Sb-](Cl)(Cl)(Cl)(Cl)Cl.BrC1=CC=C(C=C1)[N+](C1=CC=C(Br)C=C1)C1=CC=C(Br)C=C1</moldb-smiles>
  <moldb-formula>C18H12Br3Cl6NSb</moldb-formula>
  <moldb-inchi>InChI=1S/C18H12Br3N.6ClH.Sb/c19-13-1-7-16(8-2-13)22(17-9-3-14(20)4-10-17)18-11-5-15(21)6-12-18;;;;;;;/h1-12H;6*1H;/q+1;;;;;;;+5/p-6</moldb-inchi>
  <moldb-inchikey>SDHBPVANTRLAKE-UHFFFAOYSA-H</moldb-inchikey>
  <moldb-average-mass type="decimal">816.48</moldb-average-mass>
  <moldb-mono-mass type="decimal">809.568921616</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp>7.2</logp>
  <hmdb-id nil="true"/>
  <chembl-id nil="true"/>
  <chemspider-id nil="true"/>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference></synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM001647</chemdb-id>
  <dsstox-id nil="true"/>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00122566</susdat-id>
  <iupac>4-bromo-N,N-bis(4-bromophenyl)aniline</iupac>
  <moldb-polar-surface-area>13.59</moldb-polar-surface-area>
  <moldb-refractivity>102.08690000000003</moldb-refractivity>
  <moldb-polarizability>39.05278504903296</moldb-polarizability>
  <moldb-rotatable-bond-count>3</moldb-rotatable-bond-count>
  <moldb-acceptor-count>0</moldb-acceptor-count>
  <moldb-donor-count>0</moldb-donor-count>
  <moldb-pka-strongest-acidic nil="true"/>
  <moldb-pka-strongest-basic nil="true"/>
  <moldb-physiological-charge>1</moldb-physiological-charge>
  <moldb-number-of-rings>3</moldb-number-of-rings>
  <moldb-alogps-logp>4.60</moldb-alogps-logp>
  <moldb-alogps-logs>-8.98</moldb-alogps-logs>
  <moldb-alogps-solubility>8.57e-07 g/l</moldb-alogps-solubility>
  <kingdom>Organic compounds</kingdom>
  <superklass>Benzenoids</superklass>
  <klass>Benzene and substituted derivatives</klass>
  <subklass>Halobenzenes</subklass>
  <paper-count type="integer">16</paper-count>
  <sync-id>CED0018279</sync-id>
  <structure-inchikey>SDHBPVANTRLAKE-UHFFFAOYSA-H</structure-inchikey>
  <structure-fingerprint>2000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000800000000000000001000000000000000000000000000400000000000000000400000000000000000000000000000000000000000004000000000000000000000000000020000000000000080000000000080000000000000000000000000000000000000000000000000000400000000100004000000010000000000000000200000000000000020000000000100040000000000000000000001000000000000000000000</structure-fingerprint>
  <structure-pattern-fingerprint>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</structure-pattern-fingerprint>
  <structure-pickle type="binary" encoding="base64">776t3gAAAAAQAAAAAwAAAAAAAAAdAAAAHgAAAIABEQAgAAAAATMgKgAAAP8H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</structure-pickle>
  <structure-indexed-at type="dateTime">2026-09-19T04:00:15Z</structure-indexed-at>
</compound>
